Goldman Sachs
BNTC icon

Goldman Sachs’s Benitec Biopharma BNTC Stock Holding History

Goldman Sachs’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.38M Sell
178,041
-37,435
-17% -$444K ﹤0.01% 4537
2026
Q1 		$2.29M Buy
215,476
+41,435
+24% +$480K ﹤0.01% 4420
2025
Q4 		$2.34M Sell
174,041
-20,322
-10% -$281K ﹤0.01% 4432
2025
Q3 		$2.73M Buy
194,363
+173,369
+826% +$2.21M ﹤0.01% 4202
2025
Q2 		$246K Sell
20,994
-24,889
-54% -$348K ﹤0.01% 5555
2025
Q1 		$597K Buy
+45,883
New +$555K ﹤0.01% 5079

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Goldman Sachs's BNTC Position: Q2 2026 in Review

Goldman Sachs reduced its Benitec Biopharma (BNTC) stake by 17% in Q2 2026, selling an estimated $444K and leaving 178,041 shares worth $2.38M. The position accounts for ﹤0.01% of the portfolio, ranked #4537.

Goldman Sachs first reported a position in BNTC in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.73M in Q3 2025. 86 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Goldman Sachs held 178,041 shares of Benitec Biopharma worth $2.38M as of Q2 2026.
  • Goldman Sachs sold 37,435 Benitec Biopharma shares in Q2 2026, an estimated $444K.
  • Benitec Biopharma made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4537 holding.
  • Goldman Sachs first reported a position in Benitec Biopharma in Q1 2025 and has held it in 6 quarters since.
  • Goldman Sachs's Benitec Biopharma position peaked at $2.73M in Q3 2025.
  • 86 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.